Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review

Narrative review published in Anesth Analg (2019)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board

Research article — evidence reviewArticle reference

Evidence: Narrative reviewDesarrollo de fármacosEnsayos clínicosZaleski KL et al. · Anesthesia and analgesia, 2019

Abstract

Bivalirudin (Angiomax; The Medicines Company, Parsippany, NJ), a direct thrombin inhibitor, has found increasing utilization as a heparin alternative in the pediatric population, most commonly for the treatment of thrombosis secondary to heparin-induced thrombocytopenia. Due to the relative rarity of heparin-induced thrombocytopenia as well as the lack of Food and Drug Administration-approved indications in this age group, much of what is known regarding the pharmacokinetics and pharmacodynamics of bivalirudin in this population has been extrapolated from adult data. This narrative review will present recommendations regarding the use of bivalirudin for procedural anticoagulation in the pediatric population based on the published literature.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview

Indexed MeSH termsAdolescentAge FactorsAntithrombinsBlood CoagulationCardiac CatheterizationCardiac Surgical ProceduresCardiopulmonary BypassChildChild, PreschoolDrug Administration ScheduleDrug Dosage CalculationsHemorrhage

Resumen

Narrative review consolidating pediatric procedural bivalirudin recommendations, primarily for treatment of HIT thrombosis, with pediatric pharmacokinetics/pharmacodynamics extrapolated from adult data.

Por qué esto importa para la hirudoterapia

This narrative review synthesizes the published literature on bivalirudin—a direct thrombin inhibitor—for procedural anticoagulation in the pediatric population, most commonly for thrombosis secondary to heparin-induced thrombocytopenia. The authors note that much of the pediatric pharmacokinetic and pharmacodynamic understanding is extrapolated from adult data, owing to the rarity of HIT in children and the absence of FDA-approved indications in this age group. The abstract does not mention hirudin, leeches, or any leech-derived compound, so no defensible hirudotherapy link can be drawn from this article. This is a review article without original data, does not involve leeches or hirudotherapy, and provides practice recommendations rather than new clinical findings.

Citación

Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review.

Zaleski KL et al. · Anesthesia and analgesia, 2019

DOI

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Drug Pipeline Drug Development Direct Thrombin Inhibitors Clinical Evidence Clinical Applications Bivalirudin Anticoagulation Compounds Hemostasis Pediatrics Otolaryngology

Aviso legal — investigación y educación

La información en esta página se proporciona únicamente con fines educativos e informativos y no constituye asesoramiento médico, diagnóstico o recomendaciones de tratamiento. Los resúmenes de evidencia clínica reflejan la literatura publicada revisada por pares y no implican eficacia terapéutica fuera de los contextos autorizados por la FDA.

La autorización FDA 510(k) para sanguijuelas medicinales se limita a indicaciones específicas. Las aplicaciones en investigación y fuera de indicación se identifican como tales. Los profesionales deben consultar las directrices vigentes de la FDA, los protocolos institucionales y las normativas estatales aplicables antes del uso clínico.

ASH apoya la evaluación rigurosa basada en evidencia de todas las aplicaciones de hirudoterapia mediante ensayos clínicos controlados e investigación revisada por pares.

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026